Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

December 15, 2009; 73 (24) Articles

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

S. Salloway, R. Sperling, S. Gilman, N. C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L. S. Honig, R. Doody, C. H. van Dyck, R. Mulnard, J. Barakos, K. M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, M. Grundman
First published November 18, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181c67808
S. Salloway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Sperling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Gilman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. C. Fox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Blennow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Raskind
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Sabbagh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. S. Honig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Doody
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. H. van Dyck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Mulnard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Barakos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. M. Gregg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Lieberburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Schenk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Black
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Grundman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway, R. Sperling, S. Gilman, N. C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L. S. Honig, R. Doody, C. H. van Dyck, R. Mulnard, J. Barakos, K. M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, M. Grundman
Neurology Dec 2009, 73 (24) 2061-2070; DOI: 10.1212/WNL.0b013e3181c67808

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
3551

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Background: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.

Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale–Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline.

Results: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study “completers” and APOE ε4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE ε4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms.

Conclusions: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE ε4 carrier status.

Classification of evidence: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.

Glossary

AD=
Alzheimer disease;
ADAS-Cog=
Alzheimer's Disease Assessment Scale–Cognitive subscale;
AE=
adverse event;
APP=
amyloid precursor protein;
CDR-SB=
Clinical Dementia Rating–Sum of Boxes;
CI=
confidence interval;
DAD=
Disability Assessment for Dementia;
mITT=
modified intent-to-treat;
MMSE=
Mini-Mental State Examination;
NTB=
Neuropsychological Test Battery;
RM=
repeated measures;
SMC=
Safety Monitoring Committee;
VE=
vasogenic edema.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    • Daniel T. Laskowitz, Duke University Medical Center, Box 2900 Duke University Medical Center, Durham NC 27710danl@neuro.duke.edu
    • Brad J. Kolls
    Submitted February 22, 2010
  • Reply from the authors
    • Stephen P. Salloway, Butler Hospital/Brown University, 345 Blackstone Boulevard Providence, RI 02906ssalloway@butler.org
    • Ronald Black, M.D., Reisa Sperling, M.D., Nick Fox, M.D., Sid Gilman, M.D., Dale Schenk, Ph.D., Michael Grundman, M.D., M.P.H.
    Submitted February 22, 2010
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENT
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • APOE ε4 and bapineuzumabInfusing pharmacogenomics into Alzheimer disease therapeutics

Topics Discussed

  • Class II
  • Clinical trials Randomized controlled (CONSORT agreement)
  • Alzheimer's disease

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise